11/21/2024

Janusmed kön och genus

Janusmed kön och genus – liraglutid

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Liraglutid

Liraglutid

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Gale EA, Gillespie KM. Diabetes and gender. Diabetologia. 2001;44(1):3-15.

  2. Jansson SP, Fall K, Brus O, Magnuson A, Wändell P, Östgren CJ et al. Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden. Diabet Med. 2015;32(10):1319-28.

  3. Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol. 2006;46:635-41.

  4. Overgaard RV, Petri KC, Jacobsen LV, Jensen CB. Liraglutide 30 mg for Weight Management: A Population Pharmacokinetic Analysis. Clin Pharmacokinet. 2016;55(11):1413-1422.

  5. Food and Drug Administration (FDA). Prescribing information - Victoza (liraglutide). Drugs@FDA [www]. [updated 2017-08-01, cited 2021-07-08].

  6. Victoza (liraglutide). Summary of Product Characeristics. European Medicines Agency (EMA) [updated 2021-11-02, cited 2021-07-08]

  7. Danne T, Biester T, Kapitzke K, Jacobsen SH, Jacobsen LV, Petri KCC et al. Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years. J Pediatr. 2017;181:146-153e3.

  8. Petri KCC, Hale PM, Hofman PL, Jacobsen LV. Liraglutide pharmacokinetics and exposure-response in pediatric patients with type 2 diabetes. J Pediatr Endocrinol Metab. 2020;33(10):1289-1292.

  9. Chiefari E, Capula C, Vero A, Oliverio R, Puccio L, Liguori R, Pullano V, Greco M, Foti D, Tirinato D, Vero R, Brunetti A. Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy. Diabates Technol Ther. 2015;17(7):468-74.

  10. Horowitz M, Aroda VR, Han J, Hardy E, Rayner CK. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences. Diabates Obes Metab. 2017;16(5):672-681.

  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.]

  1. Gale EA, Gillespie KM. Diabetes and gender. Diabetologia. 2001;44(1):3-15.
  2. Jansson SP, Fall K, Brus O, Magnuson A, Wändell P, Östgren CJ et al. Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden. Diabet Med. 2015;32(10):1319-28.
  3. Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol. 2006;46:635-41.
  4. Overgaard RV, Petri KC, Jacobsen LV, Jensen CB. Liraglutide 30 mg for Weight Management: A Population Pharmacokinetic Analysis. Clin Pharmacokinet. 2016;55(11):1413-1422.
  5. Food and Drug Administration (FDA). Prescribing information - Victoza (liraglutide). Drugs@FDA [www]. [updated 2017-08-01, cited 2021-07-08].
  6. Victoza (liraglutide). Summary of Product Characeristics. European Medicines Agency (EMA) [updated 2021-11-02, cited 2021-07-08]
  7. Danne T, Biester T, Kapitzke K, Jacobsen SH, Jacobsen LV, Petri KCC et al. Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years. J Pediatr. 2017;181:146-153e3.
  8. Petri KCC, Hale PM, Hofman PL, Jacobsen LV. Liraglutide pharmacokinetics and exposure-response in pediatric patients with type 2 diabetes. J Pediatr Endocrinol Metab. 2020;33(10):1289-1292.
  9. Chiefari E, Capula C, Vero A, Oliverio R, Puccio L, Liguori R, Pullano V, Greco M, Foti D, Tirinato D, Vero R, Brunetti A. Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy. Diabates Technol Ther. 2015;17(7):468-74.
  10. Horowitz M, Aroda VR, Han J, Hardy E, Rayner CK. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences. Diabates Obes Metab. 2017;16(5):672-681.
  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.]